CytoAgents’ drug, CTO1681, uses a novel approach to prevent and treat
Cytokine Release Syndrome
How CTO1681 Works
CytoAgents’ drug candidate, CTO1681 (formerly GP1681), prevents and treats Cytokine Release Syndrome by targeting the NF-kB signaling pathway and modulating cytokine production, resulting in reduced inflammation.
NF-kB plays a critical role in the body’s natural regulation, activation, and differentiation of inflammatory T-cells.
Excessive NF-kB activation results in pro-inflammatory cytokine amplification, as seen within Cytokine Release Syndrome, which contributes to the pathogenic processes of various inflammatory diseases.
CTO1681 reduces NF-kB signaling, but does not shut it down completely, allowing for a functioning immune system.
The Advantages of CTO1681
CTO1681 provides a number of advantages over other therapeutic options in treating CRS. By combining a demonstrated, broad mechanism of action to modulate cytokine production with a well-established safety record, it is positioned to become a new best practice in medicine.
- Phase 1 Human Clinical Trial Complete
- Well Established Safety Record
- Reduces 25+ Cytokines
- Prostaglandin Agonist, Anti-Inflammatory Mechanism of Action
- Steroid Sparing Solution
- Orally Available
Unlike other approaches, CTO1681 limits the potential damage caused by an overreaction of the immune system, but spares the patient from the potential of too harsh immunosuppression associated with other potent therapies.
Our approach to treatment focuses on reducing the destructive impact of the CRS while leaving the necessary immune function intact.